STOCK TITAN

Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer

Integra LifeSciences (Nasdaq:IART) appointed Topaz Kirlew as corporate vice president and chief regulatory officer, leading global regulatory affairs and strategy.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Integra LifeSciences (Nasdaq:IART) appointed Topaz Kirlew as corporate vice president and chief regulatory officer, leading global regulatory affairs and strategy.

She previously served as interim regulatory leader, overseeing compliance, submissions, and risk mitigation, and brings over 35 years of healthcare and medical technology experience across regulatory, quality, operations, clinical, and laboratory roles.

Loading...
Loading translation...
Argus Jul 2 session
+0.89% close to close Open Argus
Details

News Market Reaction – IART

On Jul 2, the day this news came out, IART closed 0.89% above the previous close.

Data tracked by StockTitan Argus for the Jul 2 session.

Key Figures

Industry experience: more than 35 years Equity plan increase: 3,550,000 shares Paradigm ownership: 4,012,698 shares (5.16%) +5 more
Industry experience
more than 35 years
Healthcare and medical technology experience for new chief regulatory officer
Equity plan increase
3,550,000 shares
Additional common shares approved for equity awards at 2026 Annual Meeting
Paradigm ownership
4,012,698 shares (5.16%)
Schedule 13G passive stake as of 03/31/2026
Shares issued
77,886,634 shares
Common stock issued as of December 31, 2025
Treasury stock
14,398,724 shares
Common shares designated as treasury stock as of December 31, 2025
Reference share price
$11.59
IART Nasdaq closing price on February 25, 2026 cited in S-3ASR
McBreen RSU grant
31,909 RSUs
Equity award to EVP & Chief Commercial Officer on Form 4
Essig option grant
705,468 options at $15.67
Non-qualified stock options granted to President and CEO

Historical Context

5 past events · Latest: Jun 23
5 events
  1. Jun 23

    Executive appointments

    24h Move
    +0.5%

    New senior commercial leadership roles announced to support long-term growth.

  2. Jun 15

    Conference appearance

    24h Move
    -1.7%

    Company presentation scheduled at the 2026 Truist Securities MedTech Conference.

  3. Jun 02

    Conference appearance

    24h Move
    +0.0%

    CFO presentation announced for the 2026 Jefferies Global Healthcare Conference.

  4. May 08

    Conference appearance

    24h Move
    +2.6%

    CFO scheduled to present at the BofA Securities 2026 Health Care Conference.

  5. May 05

    Leadership transition

    24h Move
    +24.1%

    Stuart Essig appointed president and CEO in a permanent leadership transition.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

regulatory affairs, regulatory compliance, clinical laboratory scientist
3 terms
regulatory affairs regulatory
"Kirlew will lead Integra's global regulatory affairs organization and oversee regulatory strategy"
Regulatory affairs is the team and processes that secure and maintain government approvals, permits, and ongoing compliance for a company’s products, such as drugs, medical devices, or financial offerings. Think of them as the navigator and permit office that prepares submission paperwork, answers regulator questions, and monitors safety and labeling after launch. Their work matters to investors because regulatory timing, costs, and approval risk directly affect a product’s ability to reach markets and generate revenue.
regulatory compliance regulatory
"she provided oversight of regulatory compliance, managed active submissions"
Regulatory compliance is the process of ensuring that a company follows all applicable laws, rules, and standards set by government authorities or industry bodies. It is important to investors because it helps prevent legal penalties, financial losses, and reputational damage, contributing to the overall stability and trustworthiness of a business. Think of it as following the rules of a game to play fairly and avoid penalties.
clinical laboratory scientist medical
"She began her career as a clinical laboratory scientist, serving at leading healthcare institutions"
A clinical laboratory scientist is a trained professional who performs and interprets medical tests on blood, tissue and other samples to detect disease, measure health markers and ensure test accuracy — think of them as the diagnostic 'detectives' and quality-control experts inside a lab. Investors care because their work determines how reliable and fast a company’s testing services are, affects regulatory compliance and operating costs, and therefore influences patient trust, revenue, and risk exposure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Kirlew will lead Integra’s global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution.

PRINCETON, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced the appointment of Topaz Kirlew, DBA, MBA, as corporate vice president and chief regulatory officer. Kirlew will lead Integra's global regulatory affairs organization and oversee regulatory strategy, compliance, submissions, and transformation initiatives worldwide.

Kirlew served as the interim regulatory leader for the company over the past several months, leading the global regulatory organization during an important period for the company. In her interim capacity, she provided oversight of regulatory compliance, managed active submissions, and led risk mitigation efforts across the organization.

"Topaz brings deep regulatory experience, sound judgment, and a practical approach to helping the business move forward the right way," said Stuart Essig, chairman and chief executive officer of Integra LifeSciences. "She has earned the confidence of the leadership team, and I am pleased to have her in this role as we continue to strengthen our regulatory capabilities and advance our mission of restoring patients' lives."

Since joining Integra in 2021, Kirlew has played a key role in building the company's regulatory capabilities and advancing key business priorities. She brings more than 35 years of healthcare and medical technology industry experience spanning regulatory affairs, quality, operations, and clinical functions.

Prior to joining Integra, Kirlew held positions of increasing responsibility at several healthcare and medical technology organizations, including Danaher Corporation, Apyx Medical, Bio-Tissue, and the University of Miami's Diabetes Research Institute. She began her career as a clinical laboratory scientist, serving at leading healthcare institutions including the National Institutes of Health, Georgetown University Hospital, and the University of Maryland Medical Center.

Kirlew earned a bachelor’s degree in clinical laboratory science from Florida International University and holds a master's degree and a doctorate in business administration from Nova Southeastern University's School of Business and Entrepreneurship.

About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra and its products, please visit www.integralife.com.

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1a23fae4-98d6-4910-9b3a-5172804e1e1c


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What role was Topaz Kirlew appointed to at Integra LifeSciences (NASDAQ:IART) on July 2, 2026?

Topaz Kirlew was appointed corporate vice president and chief regulatory officer at Integra LifeSciences. According to Integra, she will lead the global regulatory affairs organization and oversee regulatory strategy, compliance, submissions, and transformation initiatives worldwide for the company.

What are the responsibilities of Integra LifeSciences’ new chief regulatory officer for IART?

The chief regulatory officer will lead Integra’s global regulatory affairs organization and oversee regulatory strategy, compliance, and submissions. According to Integra, the role also includes guiding regulatory transformation initiatives as the company continues strengthening quality, compliance, and execution across its global operations.

What experience does Topaz Kirlew bring to Integra LifeSciences as chief regulatory officer (IART)?

Topaz Kirlew brings more than 35 years of healthcare and medical technology industry experience. According to Integra, her background spans regulatory affairs, quality, operations, and clinical functions, including roles at Danaher, Apyx Medical, Bio-Tissue, and leading healthcare and research institutions.

How did Topaz Kirlew contribute to Integra LifeSciences before becoming chief regulatory officer for IART?

Before her appointment, Kirlew served as Integra’s interim regulatory leader. According to Integra, she oversaw regulatory compliance, managed active submissions, led risk mitigation efforts, and played a key role in building the company’s regulatory capabilities since joining the organization in 2021.

What is Topaz Kirlew’s educational background relevant to her new role at Integra LifeSciences (IART)?

Topaz Kirlew holds a bachelor’s degree in clinical laboratory science and advanced business degrees. According to Integra, she earned her bachelor’s from Florida International University and a master’s and doctorate in business administration from Nova Southeastern University’s School of Business and Entrepreneurship.

Keep reading